Roluperidone

Roluperidone is an investigational antipsychotic drug that is being developed by Minerva Neurosciences for the treatment of schizophrenia and Parkinson's disease. It is a selective antagonist of the serotonin 5-HT2A receptor and the sigma receptors σ1 and σ2, and does not significantly affect other neurotransmitter receptors.

Mechanism of action

Roluperidone acts as a selective antagonist at the serotonin 5-HT2A receptor and the sigma receptors σ1 and σ2. This means it blocks the action of serotonin and sigma receptors, which are involved in the regulation of mood, cognition, and perception. This mechanism of action is different from most other antipsychotic drugs, which primarily act by blocking the dopamine D2 receptor.

Clinical trials

Roluperidone has been tested in several clinical trials for its effectiveness in treating schizophrenia and Parkinson's disease. In a Phase IIb clinical trial, roluperidone demonstrated a significant improvement in the negative symptoms of schizophrenia compared to placebo. A Phase III clinical trial is currently underway.

Side effects

The most common side effects reported in clinical trials include insomnia, nausea, and headache. However, as roluperidone is still in the experimental stages, more comprehensive data on its side effect profile is not yet available.

Development status

As of 2021, roluperidone is still in the experimental stages of development and has not yet been approved by the Food and Drug Administration (FDA) or any other regulatory authority. The drug is being developed by Minerva Neurosciences, a biopharmaceutical company focused on the development of therapies for central nervous system disorders.

See also

• Antipsychotic
• Schizophrenia
• Parkinson's disease
• Clinical trial
• Serotonin
• Sigma receptor
• Minerva Neurosciences

Roluperidone Resources
Latest articles Most recent articles Ongoing trials	Wikipedia